10X Genomics (TXG) Investor Presentation - Slideshow

Company Overview - 10x Genomics has over 2,400 installed instruments[6] - The company's consumable pull-through is over $150,000[6] - 10x Genomics holds over 1,100 patents and applications[6] - There are over 2,500 publications referencing 10x Genomics' technology[6] - Approximately 50% of sales are outside the US[15] Product Platforms and Market Opportunity - The company operates across three product platforms: Chromium Single Cell, Visium Spatial, and In Situ[26] - 10x Genomics addresses a global life science research tools market estimated at $15 billion[32, 33] - The company sees a downstream clinical applications market opportunity for In Situ analysis of $10 billion[35, 36] New Product Initiatives - The company launched the CellPlex Kit in Q1 2021, reducing all-in cost by approximately 60%[41, 56] - The Low Throughput Kit launched in Q2 2021, reducing startup cost by over 60%[44, 56] - Visium for FFPE is coming in Q2 2021, solving the challenge of FFPE samples[61]